NeOnc Technologies Holdings, Inc. (NTHI)
| Market Cap | 87.48M -33.3% |
| Revenue (ttm) | 39,990 +100.0% |
| Net Income | -45.86M |
| EPS | -1.93 |
| Shares Out | 27.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 225,071 |
| Open | 3.460 |
| Previous Close | 3.480 |
| Day's Range | 3.100 - 3.560 |
| 52-Week Range | 2.501 - 11.377 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 17.00 (+439.68%) |
| Earnings Date | Nov 5, 2026 |
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra... [Read more]
Financial Performance
In 2025, NTHI's revenue was $39,990, a decrease of -51.82% compared to the previous year's $83,000. Losses were -$62.15 million, 422.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NTHI stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 439.68% from the latest price.
News
NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23
CALABASAS, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for ce...
NeOnc Technologies reports updated interim results from NEO100-01 study
NeOnc Technologies (NTHI) reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade...
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
Objective response rate was 12.5% (3 of 24 patients) by RANO 2.0, compared with 8.3% (2 of 24 patients) in the August topline results Median overall survival was 26.1 months from the start of NEO100 t...
NeOnc CEO Amir Heshmatpour's 2026 Open-Market Share Purchases Exceed $1.5 Million
CALABASAS, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) today announced that Amir F.
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
NeOnc (NASDAQ: NTHI) to present findings from 2 investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO)
NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market, bringing his ...
NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insid...
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and...
NeOnc granted Type B End-of-Phase meeting by FDA for intranasal NEO100
NeOnc Technologies (NTHI) announced that the FDA has granted the company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progres...
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for ce...
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
DALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for...
NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
CALABASAS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for ce...
NeOnc Technologies Holdings Quarterly report: Q3 2026
NeOnc Technologies Holdings has published its Q3 2026 quarterly earnings report on November 5, 2026.
NeOnc Technologies Holdings Earnings release: Q3 2026
NeOnc Technologies Holdings released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
DENVER, Nov. 02, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com) — In a market where the latest investment trends often dominate attention, NeOnc Technologies Holdings (NASDAQ: NTHI) is developing a s...
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
CALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for ce...
NeOnc's Ambitious Brain Cancer Plans are Setting the Stage
DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com) — In a market where the latest whizbang trends often dominate investor attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing ...
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is setting its sights on a substantially larger international clinical effort, outlining pl...
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue
DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, delivering a potentially impo...
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight
NeOnc (NASDAQ: NTHI) is taking its brain cancer story to Fox Business Network when several developments put the clinical-stage biotech in the spotlight
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
CALABASAS, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for ce...
NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development story Houston, Texas--(Newsfile Corp. - October 21, 2026) - As NeO...
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
DENVER, Oct. 21, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) — “I wish someone had told me about that company.” That is a familiar reaction when a stock attracts attention after investors have spen...
NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu ...
Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season
DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- At an ugly-sweater party, the one with the most flair gets everyone talking. On Wall Street, attention can shift just as quickly when...